XPrize Foundation
Coverage of XPrize Foundation in the Nexus archive.
- The Download: whole-body rejuvenation drugs and five things to know about AI
David Sinclair plans to test whole-body rejuvenation drugs in a $101 million XPrize competition aiming to reverse aging through human trials. The article also covers AI developments, including OpenAI's confidential IPO filing and U.S.-China tech tensions involving companies like BYD and Baidu.
- David Sinclair plans to test whole-body rejuvenation drugs in the XPrize competition
David Sinclair, a longevity scientist, plans to test an oral reprogramming drug in human trials as part of a $101 million XPrize competition aimed at restoring apparent age through improvements in immune, cognitive, and muscle function. His Harvard-affiliated work involves epigenetic reprogramming, which resets molecular DNA controls, and his company Life Biosciences has already initiated gene therapy trials for eye conditions.